ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Shionogi, Pfizer and Merck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Shionogi×Pfizer×Merck×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

ShionogiPfizerMerck
studies on the registry1574,0732,455
open to participants now10147146
phase 3 studies under way399112
reach primary completion within a year69259
programswith a study of their own in two years1391+9 named only84

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseShionogiPfizerMerck
Phase 1

Shionogi: 4 of its 13 programs at phase 1

  1. sulthiamephase 1
  2. xeruborbactamphase 1
  3. JTE-162phase 1
  4. S-740792phase 1
31%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
Phase 2

Shionogi: 6 of its 13 programs at phase 2

  1. S-606001phase 2
  2. S-892216phase 2
  3. S-337395phase 2
  4. sivopixantphase 2
  5. Acetazolamidephase 2

and 1 more — sign in to see them all

46%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%
23%
Phase 3

Shionogi: 3 of its 13 programs at phase 3

  1. zatolmilastphase 3
  2. secutrelvirphase 3
  3. ensitrelvirphase 3
23%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%
Approved, new studies00%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Shionogi8 readouts · 2 phase 3·

Shionogi, Dec ’26: 5 programs whose next study reaches primary completion

  1. sulthiamephase 1 · Dec 4 · NCT07857837
  2. S-337395phase 2 · Dec 30 · NCT07214571
  3. Acetazolamidephase 2 · Dec 31 · NCT06776432
  4. SASS-001phase 2 · Dec 31 · NCT06776432
  5. sivopixantphase 2 · Dec 31 · NCT06776432
······

Shionogi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. secutrelvirphase 3 · Jul 31 · NCT07746544

Shionogi, Aug ’27: 1 program whose next study reaches primary completion

  1. S-606001phase 2 · Aug 8 · NCT07123155

Shionogi, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zatolmilastphase 3 · Sep 30 · NCT05367960
·
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Shionogi

New programs 1

  • sulthiamephase 1 · first study · Sep 29 · Renal Insufficiency

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 7

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 46 in all. A program counts in each condition its studies name most.

ConditionShionogiPfizerMerck
Renal Insufficiencyall three · compare here

Shionogi in Renal Insufficiency: 4 programs

  1. zatolmilastphase 3
  2. ensitrelvirphase 3
  3. S-892216phase 2
  4. sulthiamephase 1

Their studies: Shionogi’s studies of Renal Insufficiency in search

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

Merck in Renal Insufficiency: 7 programs

  1. calderasibphase 3
  2. nemtabrutinibphase 3
  3. alimatravirphase 3
  4. enlicitide chloridephase 3
  5. doravirinephase 3

and 2 more — sign in to see them all

Their studies: Merck’s studies of Renal Insufficiency in search

COVID-19all three · compare here

Shionogi in COVID-19: 3 programs

  1. secutrelvirphase 3
  2. ensitrelvirphase 3
  3. S-892216phase 2

Their studies: Shionogi’s studies of COVID-19 in search

Pfizer in COVID-19: 5 programs

  1. abrysvophase 3
  2. ibuzatrelvirphase 3
  3. zavegepantphase 3
  4. remdesivirphase 3
  5. PA-001phase 1

Their studies: Pfizer’s studies of COVID-19 in search

Merck in COVID-19: 2 programs

  1. molnupiravirphase 3
  2. frespaciguatphase 3

Their studies: Merck’s studies of COVID-19 in search

Alzheimer Diseaseall three · compare here

Shionogi in Alzheimer Disease: 1 program

  1. zatolmilastphase 3

Their studies: Shionogi’s studies of Alzheimer Disease in search

Pfizer in Alzheimer Disease: 1 program

  1. PF-08161842phase 1

Their studies: Pfizer’s studies of Alzheimer Disease in search

Merck in Alzheimer Disease: 3 programs

  1. MK-2214phase 2
  2. BCG Vaccinephase 2
  3. MK-1167phase 2

Their studies: Merck’s studies of Alzheimer Disease in search

Respiratory Syncytial Virus Infectionsall three · compare here

Shionogi in Respiratory Syncytial Virus Infections: 1 program

  1. S-337395phase 2

Their studies: Shionogi’s studies of Respiratory Syncytial Virus Infections in search

Pfizer in Respiratory Syncytial Virus Infections: 2 programs

  1. abrysvophase 3
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3

Their studies: Pfizer’s studies of Respiratory Syncytial Virus Infections in search

Merck in Respiratory Syncytial Virus Infections: 1 program

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Respiratory Syncytial Virus Infections in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here–

Pfizer in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 3 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasms2 of 3 · compare here–

Pfizer in Neoplasms: 2 programs

  1. polfurmetinibphase 1
  2. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Breast Neoplasms2 of 3 · compare here–

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Obesity2 of 3 · compare here–

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Merck in Obesity: 3 programs

  1. efinopegdutidephase 2
  2. TERN-601phase 2
  3. Metforminapproved, new study

Their studies: Merck’s studies of Obesity in search

Dermatitis, Atopic2 of 3 · compare here–

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

Merck in Dermatitis, Atopic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Dermatitis, Atopic in search

Colorectal Neoplasms2 of 3 · compare here–

Pfizer in Colorectal Neoplasms: 4 programs

  1. tivunatamigphase 3
  2. tusamitamab sonditecanphase 1
  3. tucatinibapproved, new study
  4. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Colorectal Neoplasms in search

Merck in Colorectal Neoplasms: 2 programs

  1. zanzalintinibphase 3
  2. Cetuximabphase 3

Their studies: Merck’s studies of Colorectal Neoplasms in search

Diabetes Mellitus, Type 22 of 3 · compare here–

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

Merck in Diabetes Mellitus, Type 2: 4 programs

  1. efinopegdutidephase 2
  2. MK-1403phase 1
  3. MK-2828phase 1
  4. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search

Melanoma2 of 3 · compare here–

Merck in Melanoma: 3 programs

  1. intismeran autogenephase 3
  2. BCG Vaccinephase 2
  3. pembrolizumabapproved, new study

Their studies: Merck’s studies of Melanoma in search

Non-Muscle Invasive Bladder Neoplasms2 of 3 · compare here–

Merck in Non-Muscle Invasive Bladder Neoplasms: 2 programs

  1. intismeran autogenephase 3
  2. BCG Vaccinephase 2

Their studies: Merck’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Pneumococcal Infections2 of 3 · compare here–

Pfizer in Pneumococcal Infections: 4 programs

  1. PG4phase 3
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3
  3. PG4 Multivalent Vaccinephase 3
  4. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Pneumococcal Infections in search

Merck in Pneumococcal Infections: 2 programs

  1. V118Cphase 1
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Pneumococcal Infections in search

Small Cell Lung Carcinoma2 of 3 · compare here–

Pfizer in Small Cell Lung Carcinoma: 3 programs

  1. tivunatamigphase 3
  2. mevrometostatphase 3
  3. tegtociclibphase 2

Their studies: Pfizer’s studies of Small Cell Lung Carcinoma in search

Merck in Small Cell Lung Carcinoma: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. gocatamigphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Small Cell Lung Carcinoma in search

Colitis, Ulcerative2 of 3 · compare here–

Pfizer in Colitis, Ulcerative: 2 programs

  1. etrasimodphase 3
  2. PF-07054894phase 1

Their studies: Pfizer’s studies of Colitis, Ulcerative in search

Merck in Colitis, Ulcerative: 3 programs

  1. tulisokibartphase 3
  2. MK-8690phase 2
  3. MK-6194phase 2

Their studies: Merck’s studies of Colitis, Ulcerative in search

Ovarian Neoplasms2 of 3 · compare here–

Pfizer in Ovarian Neoplasms: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Ovarian Neoplasms in search

Asthma2 of 3 · compare here–

Pfizer in Asthma: 3 programs

  1. tilrekimigphase 3
  2. zavegepantphase 3
  3. PF-08103402phase 1

Their studies: Pfizer’s studies of Asthma in search

Merck in Asthma: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Asthma in search

Esophageal Neoplasms2 of 3 · compare here–

Pfizer in Esophageal Neoplasms: 2 programs

  1. PF-08046033phase 1
  2. PF-08098488phase 1

Their studies: Pfizer’s studies of Esophageal Neoplasms in search

Merck in Esophageal Neoplasms: 2 programs

  1. patritumab deruxtecanphase 3
  2. Rescue Medicationsphase 2

Their studies: Merck’s studies of Esophageal Neoplasms in search

Hepatic Insufficiency2 of 3 · compare here–

Pfizer in Hepatic Insufficiency: 1 program

  1. atirmociclibphase 3

Their studies: Pfizer’s studies of Hepatic Insufficiency in search

Merck in Hepatic Insufficiency: 3 programs

  1. bomedemstatphase 3
  2. ulonivirinephase 3
  3. enlicitide chloridephase 3

Their studies: Merck’s studies of Hepatic Insufficiency in search

HIV Infections2 of 3 · compare here–

Pfizer in HIV Infections: 1 program

  1. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of HIV Infections in search

Merck in HIV Infections: 3 programs

  1. islatravirphase 3
  2. doravirinephase 3
  3. MK4646phase 1

Their studies: Merck’s studies of HIV Infections in search

Influenza, Human2 of 3 · compare here–

Pfizer in Influenza, Human: 3 programs

  1. abrysvophase 3
  2. qIRVphase 1
  3. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Influenza, Human in search

Merck in Influenza, Human: 1 program

  1. efitazanamivir alfaphase 3

Their studies: Merck’s studies of Influenza, Human in search

Sleep Apnea Syndromes2 of 3 · compare here

Shionogi in Sleep Apnea Syndromes: 3 programs

  1. sivopixantphase 2
  2. Acetazolamidephase 2
  3. SASS-001phase 2

Their studies: Shionogi’s studies of Sleep Apnea Syndromes in search

Pfizer in Sleep Apnea Syndromes: 1 program

  1. berobenatidephase 3

Their studies: Pfizer’s studies of Sleep Apnea Syndromes in search

–
Triple Negative Breast Neoplasms2 of 3 · compare here–

Pfizer in Triple Negative Breast Neoplasms: 1 program

  1. KAT6/KAT7 Inhibitor PF-08032562phase 1

Their studies: Pfizer’s studies of Triple Negative Breast Neoplasms in search

Merck in Triple Negative Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. zilovertamab vedotinphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Triple Negative Breast Neoplasms in search

Carcinoma, Transitional Cell2 of 3 · compare here–

Pfizer in Carcinoma, Transitional Cell: 1 program

  1. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Carcinoma, Transitional Cell in search

Hypertension, Pulmonary2 of 3 · compare here–

Pfizer in Hypertension, Pulmonary: 1 program

  1. PF-07868489phase 2

Their studies: Pfizer’s studies of Hypertension, Pulmonary in search

Merck in Hypertension, Pulmonary: 2 programs

  1. frespaciguatphase 3
  2. sotaterceptapproved, new study

Their studies: Merck’s studies of Hypertension, Pulmonary in search

Lupus Erythematosus, Systemic2 of 3 · compare here–

Pfizer in Lupus Erythematosus, Systemic: 2 programs

  1. dazukibartphase 3
  2. PF-08154225phase 2

Their studies: Pfizer’s studies of Lupus Erythematosus, Systemic in search

Merck in Lupus Erythematosus, Systemic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Lupus Erythematosus, Systemic in search

Pneumonia, Pneumococcal2 of 3 · compare here–

Pfizer in Pneumonia, Pneumococcal: 2 programs

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 3
  2. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Pneumonia, Pneumococcal in search

Merck in Pneumonia, Pneumococcal: 1 program

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Pneumonia, Pneumococcal in search

Pulmonary Arterial Hypertension2 of 3 · compare here–

Pfizer in Pulmonary Arterial Hypertension: 1 program

  1. PF-07868489phase 2

Their studies: Pfizer’s studies of Pulmonary Arterial Hypertension in search

Merck in Pulmonary Arterial Hypertension: 2 programs

  1. frespaciguatphase 3
  2. sotaterceptapproved, new study

Their studies: Merck’s studies of Pulmonary Arterial Hypertension in search

Sleep Apnea, Obstructive2 of 3 · compare here

Shionogi in Sleep Apnea, Obstructive: 2 programs

  1. Acetazolamidephase 2
  2. sulthiamephase 1

Their studies: Shionogi’s studies of Sleep Apnea, Obstructive in search

Pfizer in Sleep Apnea, Obstructive: 1 program

  1. berobenatidephase 3

Their studies: Pfizer’s studies of Sleep Apnea, Obstructive in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here–

Pfizer in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpha V Beta 8 Antagonist PF-06940434phase 1

Their studies: Pfizer’s studies of Squamous Cell Carcinoma of Head and Neck in search

Merck in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. Cetuximabphase 3
  2. pembrolizumabapproved, new study

Their studies: Merck’s studies of Squamous Cell Carcinoma of Head and Neck in search

Uterine Cervical Neoplasms2 of 3 · compare here–

Pfizer in Uterine Cervical Neoplasms: 2 programs

  1. tucatinibapproved, new study
  2. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Uterine Cervical Neoplasms in search

Arthritis, Rheumatoid2 of 3 · compare here–

Pfizer in Arthritis, Rheumatoid: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Arthritis, Rheumatoid in search

Merck in Arthritis, Rheumatoid: 1 program

  1. MK-8690phase 2

Their studies: Merck’s studies of Arthritis, Rheumatoid in search

Bacterial Infections2 of 3 · compare here

Shionogi in Bacterial Infections: 1 program

  1. xeruborbactamphase 1

Their studies: Shionogi’s studies of Bacterial Infections in search

–

Merck in Bacterial Infections: 1 program

  1. tedizolid phosphatephase 3

Their studies: Merck’s studies of Bacterial Infections in search

Crohn Disease2 of 3 · compare here–

Pfizer in Crohn Disease: 1 program

  1. etrasimodphase 3

Their studies: Pfizer’s studies of Crohn Disease in search

Merck in Crohn Disease: 1 program

  1. tulisokibartphase 3

Their studies: Merck’s studies of Crohn Disease in search

Diabetes Mellitus2 of 3 · compare here–

Pfizer in Diabetes Mellitus: 1 program

  1. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus in search

Merck in Diabetes Mellitus: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus in search

Endometrial Neoplasms2 of 3 · compare here–

Pfizer in Endometrial Neoplasms: 1 program

  1. tivunatamigphase 3

Their studies: Pfizer’s studies of Endometrial Neoplasms in search

Merck in Endometrial Neoplasms: 1 program

  1. sacituzumab tirumotecanphase 3

Their studies: Merck’s studies of Endometrial Neoplasms in search

Hypertension2 of 3 · compare here–

Pfizer in Hypertension: 1 program

  1. Prazosinphase 1

Their studies: Pfizer’s studies of Hypertension in search

Merck in Hypertension: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Hypertension in search

Multiple Myeloma2 of 3 · compare here–

Pfizer in Multiple Myeloma: 1 program

  1. elranatamabapproved, new study

Their studies: Pfizer’s studies of Multiple Myeloma in search

Merck in Multiple Myeloma: 1 program

  1. sotaterceptapproved, new study

Their studies: Merck’s studies of Multiple Myeloma in search

Neoplasm Metastasis2 of 3 · compare here–

Pfizer in Neoplasm Metastasis: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Neoplasm Metastasis in search

Merck in Neoplasm Metastasis: 1 program

  1. MK-8294phase 1

Their studies: Merck’s studies of Neoplasm Metastasis in search

Pneumonia2 of 3 · compare here–

Pfizer in Pneumonia: 1 program

  1. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Pneumonia in search

Merck in Pneumonia: 1 program

  1. tedizolid phosphatephase 3

Their studies: Merck’s studies of Pneumonia in search

Prostatic Neoplasms2 of 3 · compare here–

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

Merck in Prostatic Neoplasms: 1 program

  1. opevesostatphase 3

Their studies: Merck’s studies of Prostatic Neoplasms in search

Psoriasis2 of 3 · compare here–

Pfizer in Psoriasis: 1 program

  1. abrocitinibphase 3

Their studies: Pfizer’s studies of Psoriasis in search

Merck in Psoriasis: 1 program

  1. MK-8644phase 1

Their studies: Merck’s studies of Psoriasis in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

Pfizer in Pulmonary Disease, Chronic Obstructive: 1 program

  1. tilrekimigphase 3

Their studies: Pfizer’s studies of Pulmonary Disease, Chronic Obstructive in search

Merck in Pulmonary Disease, Chronic Obstructive: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Pulmonary Disease, Chronic Obstructive in search

Stomach Neoplasms2 of 3 · compare here–

Pfizer in Stomach Neoplasms: 1 program

  1. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Stomach Neoplasms in search

Merck in Stomach Neoplasms: 1 program

  1. pembrolizumabapproved, new study

Their studies: Merck’s studies of Stomach Neoplasms in search

Vitiligo2 of 3 · compare here–

Pfizer in Vitiligo: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Vitiligo in search

Merck in Vitiligo: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Vitiligo in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Shionogi 4 of 13 · Pfizer 67 of 91 · Merck 40 of 84 programs (34 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).